Vol. 7, Issue 2, Part C (2025)

Human metapneumovirus (HMPV) is a major cause of pediatric respiratory illness, with evolving antigenic variants driving reinfections, variable disease severity, and challenges in diagnosis and vaccine development. Antigenic changes, mainly in the G glycoprotein, arise from high mutation rates, repeated infections, maternal antibodies, and rapid pediatric transmission, facilitating immune escape. Although the F protein is a conserved target for vaccines, genetic diversification complicates broadly protective vaccine design. Current vaccine strategies include subunit, virus-like particle (VLP), mRNA, live-attenuated, and multi-epitope platforms informed by genomic surveillance. In the absence of licensed vaccines or antivirals, nursing plays a pivotal role in early detection, infection prevention, supportive care, parental education, and reporting, helping reduce clinical severity, limit transmission, and strengthen public health preparedness.